Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104 Post published:September 9, 2021 Post category:Press Release
Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians Post published:August 31, 2021 Post category:Press Release
Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results Post published:August 16, 2021 Post category:Press Release
Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP Post published:July 27, 2021 Post category:Press Release
Field Trip Health Ltd. Obtains Conditional Approval to List on Nasdaq Under the Symbol “FTRP” Post published:July 23, 2021 Post category:Press Release
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results Post published:June 24, 2021 Post category:Press Release
Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call for Friday, June 25, 2021 At 8:00 am ET Post published:June 17, 2021 Post category:Press Release
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound Post published:June 15, 2021 Post category:Press Release
Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market Post published:June 8, 2021 Post category:Press Release
Field Trip Health Ltd. to Commence Trading on the Toronto Stock Exchange on June 7, 2021 Post published:June 3, 2021 Post category:Press Release